Comparative Pharmacology
Head-to-head clinical analysis: FORZINITY versus QVAR REDIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORZINITY versus QVAR REDIHALER.
FORZINITY vs QVAR REDIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORZINITY (sodium-glucose cotransporter-2 inhibitor) inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
1.5 mg/kg intravenously every 4 weeks. For patients with body weight >100 kg, a fixed dose of 150 mg is recommended.
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; clinically significant for once-daily dosing in most patients.
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Primarily renal excretion (60-70% as unchanged drug) with biliary/fecal elimination accounting for 20-30%.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid